Provider Billing Guidance for COVID-19 Testing
Medicaid/OHP Coverage of COVID-19 Antibody Testing
Providers are invited to read the letter from the Oregon Health Authority to all CCOs and OHP providers regarding COVID-19 antibody testing (PDF)
Updated 6.17.2020
Medicare DRG Increases for COVID-19 Treatment Services Under Coronavirus Aid, Relief, and Economic Security (CARES) Act
The Centers for Medicare & Medicaid Services (CMS) have released guidance for implementing several provisions included in the Coronavirus Aid, Relief, and Economic Security (CARES) Act (PDF). Trillium Community Health Plan (Trillium) will be following this guidance as we adjudicate Medicare claims for applicable COVID-19 inpatient treatment services.
The CARES Act provides for a 20% increase to the inpatient prospective payment system (IPPS) Diagnosis Related Group (DRG) rate for COVID-19 patients for the duration of the public health emergency. The increase will be applied to claims that include the applicable COVID-19 ICD-10-CM diagnosis code and meet the date of service requirements, as follows:
- Discharges occurring on or after January 27 and on or before March 31:
- B97.29 – Other coronavirus as the cause of diseases classified elsewhere
- CDC Coding Guidance for cases discharging on March 31 and prior (PDF)
- Discharges occurring on or after April 1:
For discharges with the diagnosis codes above, Trillium will follow the Medicare billing guidance published by CMS (PDF). Inpatient claims for these COVID-19 discharges that have already been received will be automatically reprocessed to reflect the payment increase.
This guidance is in response to the COVID-19 pandemic and may be retired at a future date.
SOURCES:
The Centers for Medicare and Medicaid (CMS)
- New Waivers for Inpatient Prospective Payment System (IPPS) Hospitals, Long-Term Care Hospitals (LTCHs), and Inpatient Rehabilitation Facilities (IRFs) due to Provisions of the CARES Act (PDF)
- July 2020 Quarterly Update to the Inpatient Prospective Payment System (IPPS) Fiscal Year (FY) 2020 Pricer (PDF)
The Centers for Disease Control (CDC)
Coverage & Billing FAQs
updated 4/7/2020
Click the link above to visit the Coverage & Billing section on the Coronavirus FAQs page
Please refer to the websites below for the current coding guidelines for Telehealth Services
Any services that are not otherwise restricted and can be delivered virtually will continue to be eligible for telehealth coverage at this time. Beginning July 1, 2021, prior authorization requirements will be reinstated for applicable services delivered via telehealth. Providers should reflect telehealth care on their claim form by following standard telehealth billing protocols in their state.
For further coding guidance for telehealth services, we recommend following what is being published by:
- Department of Health and Human Services (HHS)
- American Medical Association (AMA)
- Centers for Commercial/Marketplace and Medicaid (CMS)
New Telehealth Policies Expand Coverage for Healthcare Services
In order to ensure that all of our members have needed access to care, we are increasing the scope and scale of our use of telehealth services for all products for the duration of the COVID-19 emergency. These coverage expansions will benefit not only members who have contracted or been exposed to the novel coronavirus, but also those members who need to seek care unrelated to COVID-19 and wish to avoid clinical settings and other public spaces.
Effective immediately, the policies we are implementing include:
- Continuation of zero member liability (copays, cost sharing, etc.) for care delivered via telehealth*
- Any services that can be delivered virtually will be eligible for telehealth coverage
- All prior authorization requirements for telehealth services will be lifted for dates of service from March 17, 2020 through June 30, 2020
- Telehealth services may be delivered by providers with any connection technology to ensure patient access to care**
- Any provider claim with a date of service beginning 3/17/20 through 6/30/2020 will have $0 member liability
- Any provider claim that is billed with a place of service of 02 will have $0 Member Liability
- Any provider claim that is billed with the following modifiers regardless of place of service billed will also be in scope:
- Modifier 95
- Modifier GT
- Modifier GQ
- Any provider claim billed with the following HCPCS/CPT codes will also be in scope for e-visits (a communication between a patient and their provider through an online patient portal):
- Medicare: 99421, 99422, 99423, G2061, G2062, G2063, G2010, G2012
- 99441, 99442, 99443, 98966, 98967, 98968 (these codes are effective 3/30)
- Medicaid: 99441, 99442, 99443, G2010, G2012,
- 98966, 98967, 98968 (these codes are effective 3/30)
- Any provider claim billed with the following revenue code:
- 780 regardless of POS or modifiers (telemedicine unspecified)
- 789 regardless of POS of modifiers
- PLEASE NOTE: Medicaid Providers please follow your state specific guidelines for telehealth billing
- Prior Auth requirements will also be waived to ease access of care requirements
- This is regardless of diagnosis
- This is across all product lines
- This is inclusive of both Par and Non Par Providers
- See the CMS Issued FAQ sheet (PDF) for additional information
*Please note: For Health Savings Account (HSA)-Qualified plans, IRS guidance is pending as to deductible application requirements for telehealth/telemedicine related services.
**Providers should follow state and federal guidelines regarding performance of telehealth services including permitted modalities.
Providers who have delivered care via telehealth should reflect it on their claim form by following standard telehealth billing protocols in their state.
We believe that these measures will help our members maintain access to quality, affordable healthcare while maintaining the CDC’s recommended distance from public spaces and groups of people.
The AMA (American Medical Association) offers special coding advice during COVID-19 public health emergency. Read the AMA advice (PDF).
Information provided by the American Medical Association does not dictate payer reimbursement policy and does not substitute for the professional judgement of the practitioner performing a procedure, who remains responsible for correct coding.
We are closely monitoring and following all guidance from the Centers for Medicare and Medicaid (CMS) as it is released to ensure we can quickly address and support the prevention, screening, and treatment of COVID-19. As of March 18, 2020, the following guidance can be used to bill for services related to COVID-19 testing.
Testing & Screening
COVID-19 Testing, Screening & Treatment Services
COVID-19 Testing Services
Providers performing the COVID-19 test can bill us for testing services that occurred after February 4, 2020, using the following newly created HCPCS codes:
COVID-19 Testing Services
Code Type | Code | Effective* |
Testing (CDC) | U0001 | 2/4/2020 |
Testing (Non-CDC) | U0002 | 2/4/2020 |
Testing (Industry Standard) | 87635 | 3/1/2020 |
Testing (Infectious Disease) | 0202U | 5/20/2020 |
Testing (Throughput) | U0003 | 4/14/2020 |
Testing (Throughput) | U0004 | 4/14/2020 |
Testing (Antigen) | 0223U | 6/25/2020 |
Testing (Antigen) | 0224U | 6/25/2020 |
Testing (Infectious Disease) | 0225U | 8/10/2020 |
Testing (sVNT) | 0226U | 8/10/2020 |
Testing | 86413 | 9/8/2020 |
Testing (Infectious Disease) | 0240U | 10/6/2020 |
Testing (Infectious Disease) | 0241U | 10/6/2020 |
Testing (Infectious Agent Detection) | 87636 | 10/6/2020 |
Testing (Infectious Agent Detection) | 87637 | 10/6/2020 |
Testing (Infectious Agent Detection) | 87811 | 10/6/2020 |
Testing (Add-On Payment) | U0005 | 1/1/2021 |
*NEW* OTC At Home COVID Tests | N/A | 1/15/2022 |
We have configured our systems to apply $0 member cost share liability for those claims submitted utilizing these codes to indicate high production testing.
Providers billing with these codes will not be limited by provider type and can be both participating and non-participating.
Reimbursement Rates for COVID-19 Services for All Provider Types
Commercial products will reimburse COVID-19 services in accordance with our negotiated commercial contract rates.
We will follow these CMS published rates except where state-specific Medicaid rate guidance should supersede.
Any additional rates will be determined by further CMS and/or state-specific guidance and communicated when available.
Updated 5.15.2020
COVID-19 Specimen Transfers
For specimen transfer related claims, the following codes can be used:
- G2023 - Spec Clct for SARS-COV-2 COVID 19 ANY SPEC SRC
- G2024 - SP CLCT SARS-COV2 COVID19 FRM SNF/LAB ANY SPEC
- C9803 - Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source. This is effective for services provided on or after March 1, 2020.
Providers billing with these codes will not be limited by provider type and can be both participating and non-participating.
COVID-19 Screening Services
All member cost share (copayment, coinsurance and/or deductible amounts) will be waived for COVID-19 screening visits and if billed alongside a COVID-19 testing code.
If no testing is performed, providers may still bill for COVID-19 screening visits for suspected contact using the following Z codes:
- Z20.822 or Z20.828 – Use these codes prior to 1/1/21 - for contact with and (suspected) exposure to COVID-19.
- Z03.818 – Exposure to COVID-19 and the virus is ruled out after evaluation
This applies to services that occurred as of February 4, 2020.
Providers billing with these codes will not be limited by provider type.
COVID-19 Treatment Services
We will waive prior authorization requirements and member cost sharing for COVID-19 treatment for all members.
As of February 4, 2020, providers should use the ICD-10 diagnosis code:
B97.29 – Confirmed Cases – other coronavirus as the cause of diseases classified elsewhere
For dates of service of April 1, 2020 and later, providers should use the ICD-10 diagnosis code:
U07.1 – 2019-nCov Confirmed by Lab Testing
As a reminder, only those services associated with screening and/or treatment for COVID-19 will be eligible for prior authorization and member liability waivers. For screening or treatment not related to COVID-19 normal copayment, coinsurance, and deductibles will apply.